## **Core Concept**
The question tests knowledge of immunotherapy agents, specifically those targeting CTLA-4 (Cytotoxic T-Lymphocyte Antigen 4), a protein receptor that downregulates the immune system. CTLA-4 inhibitors are used in the treatment of metastatic melanoma by enhancing the body's immune response against cancer cells.

## **Why the Correct Answer is Right**
Ipilimumab, sold under the brand name Yervoy, is a monoclonal antibody that acts as a CTLA-4 inhibitor. By blocking CTLA-4, ipilimumab enhances the immune response against cancer cells, making it an effective treatment for metastatic melanoma. It was the first FDA-approved CTLA-4 inhibitor and has been shown to improve survival in patients with advanced melanoma.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is blank and does not provide a valid choice.
- **Option B:** This option is also blank and does not provide a valid choice.
- **Option C:** Similarly, this option does not provide a valid choice.
- **Option D:** This option is blank as well.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that ipilimumab (Yervoy) was a landmark drug in the treatment of metastatic melanoma, offering a new hope for patients with this aggressive disease. However, it's known for its immune-related adverse effects, which can be severe and require careful management.

## **Correct Answer:** . Ipilimumab